If you don't measure it, you can't improve it: Success and shortcomings of genomic assays in early breast cancer

Cancer. 2020 Sep 1;126(17):3922-3925. doi: 10.1002/cncr.32955. Epub 2020 Jun 10.

Authors

Oana C Danciu¹, Zhengjia Chen^{2

3}, Kent F Hoskins¹

Affiliations

¹ Division of Hematology and Oncology, Department of Medicine, University of Illinois at Chicago College of Medicine, Chicago, Illinois, USA.
² Division of Epidemiology and Biostatistics, School of Public Health, University of Illinois at Chicago, Chicago, Illinois, USA.
³ Biostatistics Shared Resource Core, University of Illinois Cancer Center, Chicago, Illinois, USA.

PMID: 32521044
DOI: 10.1002/cncr.32955

No abstract available

Keywords: African American; National Cancer Database; breast cancer; multigene assays; validation.

Publication types

Editorial
Research Support, Non-U.S. Gov't

MeSH terms

Breast Neoplasms / genetics*
Breast Neoplasms / pathology
Estrogen Receptor alpha / genetics
Estrogen Receptor beta / genetics
Female
Genome, Human / genetics
Genomics*
Humans
Patient Selection*
Precision Medicine*
Receptor, ErbB-2 / genetics

Substances

ESR1 protein, human
ESR2 protein, human
Estrogen Receptor alpha
Estrogen Receptor beta
ERBB2 protein, human
Receptor, ErbB-2